Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VIR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVir Biotechnology reports Q1 2026 financial results
Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read
Key Changes
-
high
Company announced financial results for the quarter ended March 31, 2026 via press release. Specific revenue, earnings, and guidance figures are contained in the attached exhibit.
Item 2.02 verify on EDGAR → -
medium
Press release dated May 6, 2026 furnished as Exhibit 99.1. The 8-K filing itself contains no financial details beyond confirming the quarterly results announcement.
Item 9.01 verify on EDGAR →
Summary
Vir Biotechnology filed an 8-K on May 6, 2026 to announce its first quarter 2026 financial results for the period ending March 31, 2026. The filing is a standard quarterly earnings disclosure, with the actual financial data contained in an attached press release (Exhibit 99.1) rather than in the 8-K body text itself. This is routine practice for public companies reporting quarterly results.
Retail investors should review the full press release for specific revenue figures, earnings per share, cash position, and any forward guidance the company provided. The key follow-on item to watch is whether management commentary in the press release signals any changes to the company's clinical pipeline progress, partnership agreements, or cash runway—factors that typically drive biotech valuations. Without access to the press release content, no assessment of whether results beat or missed expectations can be made from this filing alone.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Vir Biotechnology filed an 8-K attaching a press release dated May 6, 2026; no material business event disclosed in the filing body.
Added in current filing · view on EDGAR →
99.1 Press Release of the Company, dated May 6, 2026
The 8-K attaches a press release dated May 6, 2026 as Exhibit 99.1. The filing body provides no detail about the press release content, so the nature and materiality of the disclosure cannot be determined from this 8-K alone.
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 6, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2026.
The company disclosed its financial results for the first quarter of 2026 ending March 31, 2026. The actual financial details are contained in the press release furnished as Exhibit 99.1, which is not included in this 8-K body text.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify